2023
Open-Label Trial of Amikacin Liposome Inhalation Suspension in Mycobacterium abscessus Lung Disease
Siegel S, Griffith D, Philley J, Brown-Elliott B, Brunton A, Sullivan P, Fuss C, Strnad L, Wallace R, Winthrop K. Open-Label Trial of Amikacin Liposome Inhalation Suspension in Mycobacterium abscessus Lung Disease. CHEST Journal 2023, 164: 846-859. PMID: 37419144, PMCID: PMC10645596, DOI: 10.1016/j.chest.2023.05.036.Peer-Reviewed Original ResearchConceptsAmikacin liposome inhalation suspensionAmikacin resistanceCulture conversionInhalation suspensionMycobacterium abscessus lung diseasePresence of macrolide resistanceEnd pointsMicrobiological end pointsMonthly sputum culturesSputum culture conversionTreatment-refractory diseaseOpen-label protocolSecondary end pointsOpen-label trialCohort of patientsCavitary diseaseSputum culturePretreatment isolatesM abscessusOpen-labelOral antimicrobialsParenteral antibioticsCompanion therapyMacrolide resistanceMultidrug therapy
2008
PIPERACILLIN/TAZOBACTAM PLUS AMIKACIN VERSUS CARBAPENEM MONOTHERAPY AS EMPIRICAL TREATMENT OF FEBRILE NEUTROPENIA IN CHILDHOOD HEMATOLOGICAL MALIGNANCIES
Yildirim I, Aytac S, Ceyhan M, Cetin M, Tuncer M, Cengiz AB, Secmeer G, Yetgin S. PIPERACILLIN/TAZOBACTAM PLUS AMIKACIN VERSUS CARBAPENEM MONOTHERAPY AS EMPIRICAL TREATMENT OF FEBRILE NEUTROPENIA IN CHILDHOOD HEMATOLOGICAL MALIGNANCIES. Pediatric Hematology And Oncology 2008, 25: 291-299. PMID: 18484473, DOI: 10.1080/08880010802016847.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAmikacinAnti-Bacterial AgentsBacteriaBacterial InfectionsCarbapenemsChildChild, PreschoolDrug Therapy, CombinationEnzyme InhibitorsFemaleHumansLeukemia, Myeloid, AcuteMaleNeutropeniaPenicillanic AcidPiperacillinPiperacillin, Tazobactam Drug CombinationPrecursor Cell Lymphoblastic Leukemia-LymphomaConceptsFebrile neutropenic episodesDuration of feverPiperacillin/tazobactamCarbapenem monotherapyNeutropenic episodesHematological malignanciesFebrile neutropeniaEmpirical treatmentInitial empirical regimenInfection-related mortalityPediatric hematological malignanciesChildhood hematological malignanciesAcute lymphoblastic leukemiaAcute myeloblastic leukemiaAmikacin combinationEmpirical regimenPTA groupCarbapenem groupLymphoblastic leukemiaTreatment modificationAntimicrobial therapyClinical trialsTreatment successAdditional antibioticsCommon cause
2005
Treatment of multiple drug-resistant tuberculosis (MDR-TB) in Iran
Mirsaeidi SM, Tabarsi P, Khoshnood K, Pooramiri MV, Rowhani-Rahbar A, Mansoori SD, Masjedi H, Zahirifard S, Mohammadi F, Farnia P, Masjedi MR, Velayati AA. Treatment of multiple drug-resistant tuberculosis (MDR-TB) in Iran. International Journal Of Infectious Diseases 2005, 9: 317-322. PMID: 16183321, DOI: 10.1016/j.ijid.2004.09.012.Peer-Reviewed Original ResearchConceptsMultiple drug-resistant tuberculosisMore second-line drugsDrug-resistant tuberculosis treatmentMDR-TB patientsMDR-TB treatmentMasih Daneshvari HospitalDrug-resistant tuberculosisSecond-line drugsAppropriate treatment regimensProbable cureDrug regimenTreatment regimenComplete followTreatment regimensTuberculosis treatmentPatientsAverage durationRegimenTreatmentDrugsCureRegimensAmikacinHospitalFollow
1988
Isolation, characterization, and cloning of a plasmid-borne gene encoding a phosphotransferase that confers high-level amikacin resistance in enteric bacilli
Gaynes R, Groisman E, Nelson E, Casadaban M, Lerner S. Isolation, characterization, and cloning of a plasmid-borne gene encoding a phosphotransferase that confers high-level amikacin resistance in enteric bacilli. Antimicrobial Agents And Chemotherapy 1988, 32: 1379-1384. PMID: 2848443, PMCID: PMC175872, DOI: 10.1128/aac.32.9.1379.Peer-Reviewed Original Research
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply